利用標準源物理衰變率計算甲狀腺攝碘率_《華西醫學》

作者：

曾宇 ,  周綠漪

四川大學華西醫院核醫學科（成都，610041）;

關鍵詞：

131I 標準源攝碘率衰變率

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

【摘要】　目的　利用標準源物理半衰期而得理論標準源計數，計算甲狀腺攝碘率的可行性。　方法　 2009年3—9月，通過實際測量標準源計數與利用標準源物理衰變速率計算的理論標準源計數的方法，分別計算209例甲狀腺功能亢進癥患者服用131I 370 kBq 4、24 h甲狀腺攝取率，行配對t檢驗分析實測與計算所得甲狀腺攝取率有無差異。　結果　實測標準源計數與理論標準源計數計算所得的甲狀腺4 h攝碘率分別為32%±16%、35%±10%，差異無統計學意義（t=1.98，P=0.20）；24 h攝碘率分別為72%±19%、69%±24%，差異無統計學意義（t=1.49，P=0.23）。　結論　利用標準源物理衰變速率計算甲狀腺的攝碘率是可行的。

引用本文： 曾宇,周綠漪. 利用標準源物理衰變率計算甲狀腺攝碘率. 華西醫學, 2011, 26(6): 930-931. doi: 復制

1.	Franklyn JA. What is the role of radioiodine uptake measurement and thyroid scintigraphy in the diagnosis and management of hyperthyroidism[J]. Clin Endocrinol, 2010, 70(1): 11-12.
2.	中華醫學會臨床技術操作規范核醫學分冊[M]. 北京: 人民軍醫出版社, 2004: 79-80.
3.	匡安仁, 李林. 核醫學[M]. 北京: 高等教育出版社, 2008: 88-89.
4.	Merrill S, Horowitz J, Traino AC, et al. Accuracy and optimal timing of activity measurements in estimating the absorbed dose of radioiodine in the treatment of Graves’ disease[J]. Phys Med Biol, 2011, 56(3): 557-571.
5.	Ross DS. Radioiodine therapy for hyperthyroidism[J]. N Engl J Med, 2011, 364(6): 542-550.
6.	AlSharif AA, Abujbara MA, Chiacchio S, et al. Contribution of radioiodine uptake measurement and thyroid scintigraphy to the differential diagnosis of thyrotoxicosis[J]. Hell J Nucl Med, 2010, 13(2): 132-137.
7.	Traino AC, Grosso M, Mariani G. Possibility of limiting the un-justified irradiation in 131I therapy of Graves’ disease: a thyroid mass-reduction based method for the optimum activity calculation[J]. Phys Medica, 2010, 26(2): 71-79.
8.	Van Isselt JW, Broekhuizen-de Gast HS. The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves’ disease[J]. Hell J Nucl Med, 2010, 13(1): 2-5.
9.	Salvatori M, Luster M. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma[J]. Euro J Nucl Med Mol Imaging, 2010, 37(4): 821-828.
10.	Kobe C, Eschner W, Wild M, et al. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I? [J]. Nucl Med Commun, 2010, 31(3): 201-205.

1. 　Franklyn JA. What is the role of radioiodine uptake measurement and thyroid scintigraphy in the diagnosis and management of hyperthyroidism[J]. Clin Endocrinol, 2010, 70(1): 11-12.
2. 　中華醫學會臨床技術操作規范核醫學分冊[M]. 北京: 人民軍醫出版社, 2004: 79-80.
3. 　匡安仁, 李林. 核醫學[M]. 北京: 高等教育出版社, 2008: 88-89.
4. 　Merrill S, Horowitz J, Traino AC, et al. Accuracy and optimal timing of activity measurements in estimating the absorbed dose of radioiodine in the treatment of Graves’ disease[J]. Phys Med Biol, 2011, 56(3): 557-571.
5. 　Ross DS. Radioiodine therapy for hyperthyroidism[J]. N Engl J Med, 2011, 364(6): 542-550.
6. 　AlSharif AA, Abujbara MA, Chiacchio S, et al. Contribution of radioiodine uptake measurement and thyroid scintigraphy to the differential diagnosis of thyrotoxicosis[J]. Hell J Nucl Med, 2010, 13(2): 132-137.
7. 　Traino AC, Grosso M, Mariani G. Possibility of limiting the un-justified irradiation in 131I therapy of Graves’ disease: a thyroid mass-reduction based method for the optimum activity calculation[J]. Phys Medica, 2010, 26(2): 71-79.
8. 　Van Isselt JW, Broekhuizen-de Gast HS. The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves’ disease[J]. Hell J Nucl Med, 2010, 13(1): 2-5.
9. 　Salvatori M, Luster M. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma[J]. Euro J Nucl Med Mol Imaging, 2010, 37(4): 821-828.
10. 　Kobe C, Eschner W, Wild M, et al. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I? [J]. Nucl Med Commun, 2010, 31(3): 201-205.

《華西醫學》

利用標準源物理衰變率計算甲狀腺攝碘率

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《華西醫學》

利用標準源物理衰變率計算甲狀腺攝碘率

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料